Evaluation of prognostic biomarkers in meningiomas and their clinical implications in settings with limited resources.

ABSTRACT:

Background

The 5th edition of the World Health Organization (WHO) Central Nervous System (CNS) tumor classification for meningiomas acknowledges the clinical relevance of genomic profiling studies and emphasizes the importance of incorporating molecular information alongside histopathological features, leading to more accurate diagnoses and improved patient care.

Methods

We analyzed 206 meningioma samples (108 histological grade 1, 89 grade 2, and 9 grade 3) to study pTERT mutations, CDKN2A/B homozygous deletion, loss of H3K27me3, and p16 expression. The association of these molecular markers with survival outcomes was also assessed.

Results

pTERT mutation was found in 4.85% of cases, predominantly occurring in histological grade 2 (11.24%), while

SUBMITTER: Singh J 

PROVIDER: S-EPMC11241373 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature